Company Description

Alzinova is a Swedish biopharma company in the clinical phase of developing a therapeutic vaccine and a monoclonal antibody targeting Alzheimer’s disease. The company’s leading drug candidate – the ALZ-101 vaccine – is currently undergoing a clinical ph Ib trial, with topline results for part A reported during Q4 2023. The company’s other drug candidate – the ALZ-201 monoclonal antibody – is in preclinical studies in preparation for a ph Ib trial.

Sector: Biopharma
Market: First North Stockholm
Ticker: ALZ

Webpage
Penser Play

 

 

Latest research | 11 Dec 2023 | Alzinova

Therapeutic Alzheimer's vaccine in the…

Read research